Tallahassee Journal

DelveInsight’s, “Multiple Sclerosis Pipeline Insight, 2023,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Multiple sclerosis pipeline landscape. It covers the Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Multiple Sclerosis Pipeline Report

• DelveInsight’s Multiple Sclerosis pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Multiple Sclerosis treatment.
• The leading companies working in the Multiple Sclerosis market include TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
• Promising Multiple Sclerosis Pipeline Therapies in the various stages of development include rHIgM22, CNTO 1275, Interferon beta-1a (Rebif), Alemtuzumab, IMS001, ALKS 8700, Curcumin, Fingolimod, Rebif, Ocrelizumab, Evobrutinib, and others.
• On June 2023, EMD Serono Research & Development Institute Inc. announced a study of Phase 2 Clinical Trials for Evobrutinib and Tecfidera. The aim of this protocol is to find out about the safety and effectiveness of M2951 in participants with relapsing multiple sclerosis. Participants were placed into 1 of 3 groups to receive M2951, placebo or tecfidera for 24 weeks. After 24 weeks, the participants on placebo were given M2951.
• On September 2023, Hoffmann-La Roche announced a study of Phase 3 Clinical Trials for Ocrelizumab and Fingolimod. This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.

Request a sample and discover the recent advances in Multiple Sclerosis Treatment Drugs @ Multiple Sclerosis Pipeline Report

The Multiple Sclerosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Multiple Sclerosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Multiple Sclerosis clinical trial landscape.

Multiple Sclerosis Overview

Multiple sclerosis (MS) is a chronic disease affecting the central nervous system (the brain and spinal cord).MS occurs when the immune system attacks nerve fibers and myelin sheathing (a fatty substance that surrounds/insulates healthy nerve fibers) in the brain and spinal cord.

Find out more about Multiple Sclerosis Treatment Drugs @ Drugs for Multiple Sclerosis Treatment

Multiple Sclerosis Emerging Drugs Profile

• Ublituximab: TG Therapeutics
• IMU-838: Immunic
• ATA188: Atara Biotherapeutics
• ANK-700: ANOKION

Multiple Sclerosis Pipeline Therapeutics Assessment

The Multiple Sclerosis pipeline report proffers an integral view of the Multiple Sclerosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Learn more about the emerging Multiple Sclerosis Pipeline Therapies @ Multiple Sclerosis Clinical Trials Assessment

Scope of the Multiple Sclerosis Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Companies- TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
• Pipeline Therapies- rHIgM22, CNTO 1275, Interferon beta-1a (Rebif), Alemtuzumab, IMS001, ALKS 8700, Curcumin, Fingolimod, Rebif, Ocrelizumab, Evobrutinib, and others.

Dive deep into rich insights for new drugs for Multiple Sclerosis Treatment, Visit @ Multiple Sclerosis Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Multiple sclerosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Multiple sclerosis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Ublituximab: TG Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. EHP 101: Emerald Health Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ASLAN 003: ASLAN Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Lucid MS: FSD Pharma
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Multiple sclerosis Key Companies
21. Multiple sclerosis Key Products
22. Multiple sclerosis- Unmet Needs
23. Multiple sclerosis- Market Drivers and Barriers
24. Multiple sclerosis- Future Perspectives and Conclusion
25. Multiple sclerosis Analyst Views
26. Multiple sclerosis Key Companies
27. Appendix

For further information on the Multiple Sclerosis Pipeline therapeutics, reach out to Multiple Sclerosis Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting